Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/153652
Full metadata record
DC FieldValueLanguage
dc.creatorFernández-Bertólez, N-
dc.creatorCosta, C-
dc.creatorBrandão, F-
dc.creatorTeixeira, JP-
dc.creatorPásaro, E-
dc.creatorValdiglesias, V-
dc.creatorLaffon, B-
dc.date.accessioned2023-11-07T15:51:02Z-
dc.date.available2023-11-07T15:51:02Z-
dc.date.issued2022-
dc.identifier.issn2214-8019-
dc.identifier.issn0065-2598-
dc.identifier.urihttps://hdl.handle.net/10216/153652-
dc.description.abstractIron oxide nanoparticles (ION), with unique magnetic properties, have attracted huge scientific attention for a wide variety of uses, mostly in the biomedical field, due to their high biocompatibility, ability to cross biological membranes, appropriate surface architecture and easy conjugation with targeting ligands. Their current applications include diagnostic imaging, cell labelling, site-directed drug delivery and anticancer hyperthermia therapy. The ION surface may be modified by coating with different materials, aiming to stabilize the nanoparticles in different environments, to allow biomolecule binding favouring surface attachments with several molecules, and to prolong the recognition time by the immune system. Although the potential benefits of ION are considerable, and more and more ION are being manufactured to meet the demands of the rapidly proliferating field of nanomedicine, there is an urgent need to define their toxicological profile in order to avoid any potential health risks associated with their exposure and to reach optimal benefits of their use. The purpose of this chapter is to de-scribe the current knowledge on the ION toxicological features, addressing their structure and physicochemical characteristics, main exposure pathways and toxicokinetic aspects, interaction with cells, and their toxic effects, with special attention to those at the cellular and molecular level. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.pt_PT
dc.description.sponsorshipFunding text 1: Acknowledgments The present work was supported by Xunta de Galicia (reference ED431B 2019/02), Ministerio de Ciencia e Innovación (PID2020-114908GA-I00), TOXI-NANO (SEM2021-A1), NeuroiNPact (SEM2021-B2), NanoBioBarriers (PTDC/ MED-TOX/31162/2017) funded by Operational Program for Competitiveness and Internationalisation through European Regional Development Funds (FEDER/FNR) and through national funds by the Portuguese Foundation for Science and Technology (FCT), and NanoLegaTox (PTDC/SAU-PUB/29651/2017) project co-financed by COMPETE 2020, Portugal 2020 and European Union, through FEDER. Vanessa Valdiglesias was supported by Ministerio de Educación, Cultura y Deporte (reference BEAGAL18/00142), and Fátima Brandão by the Portuguese Foundation for Science and Technology (SFRH/BD101060/2014). Authors would also like to acknowledge COST Action CA17140 “Cancer nanomed-icine– from the bench to the bedside (NANO2CLINIC)”.; Funding text 2: The present work was supported by Xunta de Galicia (reference ED431B 2019/02), Ministerio de Ciencia e Innovación (PID2020-114908GA-I00), TOXI-NANO (SEM2021-A1), NeuroiNPact (SEM2021-B2), NanoBioBarriers (PTDC/ MED-TOX/31162/2017) funded by Operational Program for Competitiveness and Internationalisation through European Regional Development Funds (FEDER/FNR) and through national funds by the Portuguese Foundation for Science and Technology (FCT), and NanoLegaTox (PTDC/SAU-PUB/29651/2017) project co-financed by COMPETE 2020, Portugal 2020 and European Union, through FEDER. Vanessa Valdiglesias was supported by Ministerio de Educación, Cultura y Deporte (reference BEAGAL18/00142), and Fátima Brandão by the Portuguese Foundation for Science and Technology (SFRH/BD101060/2014). Authors would also like to acknowledge COST Action CA17140 “Cancer nanomedicine – from the bench to the bedside (NANO2CLINIC)”.pt_PT
dc.language.isoengpt_PT
dc.publisherSpringerpt_PT
dc.relation.ispartofAdv Exp Med Biol. 2022;1357:303-350-
dc.rightsrestrictedAccesspt_PT
dc.titleToxicological Aspects of Iron Oxide Nanoparticlespt_PT
dc.typeCapítulo ou Parte de Livropt_PT
dc.contributor.uportoInstituto de Saúde Públicapt_PT
dc.identifier.doi10.1007/978-3-030-88071-2_13-
dc.relation.publisherversionhttps://link.springer.com/chapter/10.1007/978-3-030-88071-2_13-
Appears in Collections:ISPUP - Capítulo ou Parte de Livro

Files in This Item:
File Description SizeFormat 
fernandez-bertolez-2022-CPL.pdf
  Restricted Access
1.76 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.